Guardion Health Sciences, Inc. (GHSI)
- Previous Close
0.0000 - Open
3.2200 - Bid 3.2300 x 45100
- Ask 3.2900 x --
- Day's Range
3.2200 - 3.2200 - 52 Week Range
3.0400 - 18.0000 - Volume
664 - Avg. Volume
108,343 - Market Cap (intraday)
4.347M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-4.1100 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield 20.00 (174.67%)
- Ex-Dividend Date Sep 24, 2024
- 1y Target Est
--
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
www.guardionhealth.com9
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GHSI
View MorePerformance Overview: GHSI
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GHSI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GHSI
View MoreValuation Measures
Market Cap
4.35M
Enterprise Value
-1.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.34
Price/Book (mrq)
0.32
Enterprise Value/Revenue
0.70
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
52.13%
Return on Assets (ttm)
-15.53%
Return on Equity (ttm)
-50.26%
Revenue (ttm)
12.23M
Net Income Avi to Common (ttm)
-5.28M
Diluted EPS (ttm)
-4.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
14.82M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
1.38M